Tamoxifen for early breast cancer: better late than never.

Keywords

Medicine, Tamoxifen, Oncology, Breast cancer, Internal medicine

References

• Early stopping of a clinical trial when there is evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project.James J. Dignam, John Bryant, H. Samuel Wieand — 1998
• Tamoxifen for early breast cancer: an overview of the randomised trialsEarly Breast Cancer Tr.group, -, Klijn, Jan — 1998
• Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. Current Trials working Party of the Cancer Research Campaign Breast Cancer Trials Group.Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group — 1996
• UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years.Richárd Pető, Jillian Boreham, Mike Clarke — 2000
• Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burdenPaola Pisani, Donald Maxwell Parkin, Jacques Ferlay — 1993
• Short term vs lifelong adjuvant tamoxifen in early breast cancer (EBC): A randomized trial (TAM-01)T. Delozier, M. Spielmann, Josette Macé-Lesec’h — 1997
• Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group.The Scottish Cancer Trials Breast Group, H.V.A. STEWART, AP Forrest — 1996
• Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial)T. Delozier, O. Switsers, J.-Y. Génot — 2000
• Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.D. C. Tormey, R Gray, H. C. Falkson — 1996
• Five years of tamoxifen--or more?Richárd Pető — 1996
• Adjuvant tamoxifen: how long before we know how long?D. Rea, Christopher Poole, Richard Gray — 1998

Cited by

• The Role of ERK5 in Cell ProliferationDiana Perez Madrigal — 2013
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.2005
• Pharmacogenetics in the Management of Breast Cancer – Prospects for Individualised TreatmentFiona Blackhall, Sacha J. Howell, Bill Newman — 2005
• Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen.Christina Davies — 2004
• Combining trastuzumab (Herceptin) with hormonal therapy in breast cancer: what can be expected and why?Alison Jones — 2003
• Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialChristina Davies, Hongchao Pan, Jon Godwin — 2013
• Lymph node metastasis and high serum CEA are important prognostic factors in hormone receptor positive and HER2 negative breast cancer.Yoshimasa Kosaka, Naoko Minatani, Yôko Tanaka — 2018
• Chemotherapy and hormonal therapy for early breast cancer : Effects on recurrence and 15-year survival in an overview of the randomised trials2005

Related papers

• The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growthC. Kent Osborne, Michael Jarman, R. MCCAGUE — 2004
• The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growthEster B. Coronado, Susan G. Hilsenbeck, Alan E. Wakeling — 1994
• Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.R. C. Dardes, Ruth O’Regan, Csaba Gajdos — 2002
• Tamoxifen (antiestrogen) therapy in advanced breast cancer.David T. Kiang, BJ. KENNEDY — 1977
• Serum tamoxifen concentrations in the athymic nude mouse after three methods of administrationMichaelW. DeGregorio, BruceJ. Wilbur, Ester B. Coronado — 2004
• [Effects of the treatment with an antiestrogen(tamoxifen) and levodopa on the secretion of prolactin in patients affected by breast cancer].Di Benedetto G, Andrea Gallamini, Nizzo Mc — 1976
• Tumor and serum tamoxifen concentrations in the athymic nude mouseMichaelW. DeGregorio, Ester B. Coronado, C. Kent Osborne — 2004
• Abstract 716: O6-Methylguanine DNA methyl transferase (MGMT) and tamoxifen resistance in patients with breast cancerSanthi D. Konduri, Sreeram Maddipatla, J. R. Smith — 2011
• Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer.Surinder K. Chander, R. MCCAGUE, Yunus A. Luqmani — 1991